TARSONS319.00

Tarsons Products Limited

· Pharma & Health
₹ CrorePeersFISCHERLAXMIDENTLFABTECHGKBMcap ₹1,697 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)745.49574.82649.07649.07
Receivable Days (DSO)95.9174.0573.7773.77
Payable Days (DPO)84.7971.64101.5893.41
Cash Conversion Cycle (days)756.61577.23621.26629.43
Working Capital Turnover13.405.87270.15282.22
Asset Turnover0.300.360.360.36
Cash Conversion (CFO/Net Income)2.413.848.278.27
CFO/EBITDA1.031.031.001.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.